Background The cardiovascular complications of cancer therapeutics are the focus of the
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …

Destruction of the established tumour vasculature by a class of compound termed Vascular
Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the …

For the first time combretastatins were isolated from African willow tree Combretum Caffrum.
Subsequent studies have shown the impact of combretastatin A4 phosphate, a water …

Several prodrugs of the naturally occurring combretastatins have undergone extensive
clinical evaluation as vascular targeting agents (VTAs). Their increased selectivity toward …

Cancer combination therapy based on drug co-delivery systems provides an effective
strategy for enhancing treatment efficacy and reducing side effects. In this work, a new …

A hybrid nanocarrier for reducing the off‐target adverse effects of chemotherapy via
selective drug delivery to the tumor cells is reported. The model active agent, combretastatin …

In an attempt to discover a potent and selective anticancer agent, gallic acid has been
modified to benzylidene indanones as tubulin polymerization inhibitors. These compounds …

A series of conformationally flexible furan-derived allocolchicinoids was prepared from
commercially available colchicine in good to excellent yields using a three-step reaction …

Abstract Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor
blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models …

VDAs represent a unique class of anticancer compounds. Their clinical development is
hampered by cardiovascular, neurological toxicities as single agent and by hematological …